Using Soliris for PNH lowers blood clot, mortality risk: Study
Soliris (eculizumab) treatment was associated with a nearly 50% reduction in mortality risk and a 60% lower risk of blood clots or other major blood vessel-related events in people with paroxysmal nocturnal hemoglobinuria (PNH), according to data from a global registry study. Those having the greatest survival benefits…